Showing 98,041 - 98,060 results of 101,164 for search '(( 5 ((step decrease) OR (teer decrease)) ) OR ( 5 ((a decrease) OR (mean decrease)) ))', query time: 1.66s Refine Results
  1. 98041

    Table_1_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.docx by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  2. 98042

    Image_3_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  3. 98043

    miR-22 directly targets <i>MECOM</i> mRNA to regulate monocyte/macrophage differentiation. by Chao Shen (520343)

    Published 2016
    “…The arrows pointed differentiated monocytes/macrophages. A statistical analysis for counting differentiated monocyte/macrophages in five fields is presented in the right. …”
  4. 98044

    Cell Types and their Rules. by Bryan Shin (17833689)

    Published 2024
    “…Simulation experiments then revealed significantly decreased B-cell responsiveness as levels of background chronic inflammation increased, reproducing the different COVID-19 infection data seen in a VA population.…”
  5. 98045

    Data_Sheet_2_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  6. 98046

    Table_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  7. 98047
  8. 98048

    Image_2_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  9. 98049

    Cytokines, Chemokines, and their Functions. by Bryan Shin (17833689)

    Published 2024
    “…Simulation experiments then revealed significantly decreased B-cell responsiveness as levels of background chronic inflammation increased, reproducing the different COVID-19 infection data seen in a VA population.…”
  10. 98050

    Image_4_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  11. 98051

    Data_Sheet_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  12. 98052

    Image_1_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  13. 98053

    Image_6_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  14. 98054
  15. 98055

    Data_Sheet_1_Blended Online Intervention to Reduce Digital Transformation Stress by Enhancing Employees’ Resources in COVID-19.PDF by Ewa Makowska-Tłomak (12274889)

    Published 2022
    “…In a longitudinal study, we examined the change in DTS, perceived stress at work, attitudes toward DT, self-efficacy and burnout in two time points, before and after the intervention. …”
  16. 98056
  17. 98057
  18. 98058
  19. 98059

    Data Sheet 1_Exploring the therapeutic potential of “Zhi-Zhen” formula for oxaliplatin resistance in colorectal cancer: an integrated study combining UPLC-QTOF-MS/MS, bioinformatic... by Yongjing Li (3821944)

    Published 2025
    “…Background<p>Chemoresistance is a critical factor compromising the survival of patients with colorectal cancer (CRC). …”
  20. 98060